WGO Graded Evidence: Management of Acute Viral Hepatitis

Level: Clinical Trials: 18 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	A randomized controlled trial of lamivudine to treat acute hepatitis B. M Kumar, S Satapathy, R Monga, K Das, S Hissar, C Pande, BC Sharma, SK Sarin, Hepatology. 2007 Jan:97-101
	Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group, Hepatology. 2008 Jul;48(1):99-108
	Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. SM Kamal, AE Fouly, RR Kamel, B Hockenjos, A Al Tawil, KE Khalifa, Q He, MJ Koziel, KM El Naggar, J Rasenack, NH Afdhal, Gastroenterology. 2006 Mar:632-8
	Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM, Am J Gastroenterol. 2008 Aug;103(8):1981-8 Cat:
	A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ, Hepatology. 2008 Mar;47(3):844-53
	Duration of peginterferon therapy in acute hepatitis C: a randomized trial. SM Kamal, KN Moustafa, J Chen, J Fehr, A Abdel Moneim, KE Khalifa, LA El Gohary, AH Ramy, MA Madwar, J Rasenack, NH Afdhal, Hepatology. 2006 May:923-31
	Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Hepatology. 2008 Jun;47(6):1884-93
	The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. Loguercio C, Federico A, Masarone M, Torella R, Blanco Cdel V, Persico M, Am J Gastroenterol. 2008 Dec;103(12):3159-66 Cat:
	Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S, Hepatology. 2008 Nov;48(5):1404-11 Cat:
	Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P, Gastroenterology. 2008 Nov;135(5):1561-7
Supplementary evidence:
	A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E, Hepatology. 2008 Nov;48(5):1460-6
	Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R, Am J Gastroenterol. 2008 Nov;103(11):2776-83
	Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F, Hepatology. 2008 Sep;48(3):750-8
	Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection. Schwarz KB, Zellos A, Stamato L, Boitnott J, Perlman E, Chong S, Casella JF, J Pediatr Gastroenterol Nutr. 2008 Apr;46(4):423-8
	Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. H Nomura, S Sou, H Tanimoto, T Nagahama, Y Kimura, J Hayashi, H Ishibashi, S Kashiwagi, Hepatology. 2004 May:1213-9
	The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, Siwak E, Cielniak I, Higersberger J, Kierkus J, Aeschlimann C, Grosgurin P, Nicolas-Métral V, Dumont JM, Porchet H, Crabbé R, Scalfaro P, Hepatology. 2008 Mar;47(3):817-26
	Three times weekly versus daily dose alpha-interferon treatment in patients with acute hepatitis C. P Fabris, G Tositti, MT Giordani, D Infantolino, LF de, Am J Gastroenterol. 2002 Feb:492-3
	Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. J Delwaide, N Bourgeois, C Gérard, S De Maeght, F Mokaddem, E Wain, B Bastens, J Fevery, M Géhénot, O Le Moine, JP Martinet, G Robaeys, B Servais, M Van Gossum, H Van Vlierberghe, Belgian Association for the Study of the Liver (BASL), Aliment Pharmacol Ther. 2004 Jul 1:15-22